Menu

hyperCORE International 's NASH Capabilities

Experience and Quality
Streamlined

  • Over 56 NASH studies conducted
  • 45 sites capable of conducting NASH trials
  • Efficient pre-screening process with over 6,800 pre-screenings conducted each year
  • Over 50% of hyperCORE sites have access to FibroScan® technology
  • Database with over 330,000 high-risk patients
  • Over 200,000 Latino and South Asians in patient databases with high-NASH incidence
  • Access to liver biopsies, specialized MRI-PDFF and MRE

Partner Highlights

FOMAT Medical Research has access to over 60 gastroenterologists, on-site DEXA & FibroScan imaging, along with a 3rd party mobile vendor for imaging.

Centricity Research has on-site DEXA & FibroScan imaging at multiple locations in the United States and Canada, access to over 100 gastroenterologists and endocrinologists, and is presently conducting a Canadian NASH registry trial.

 MOORE Clinical Research has access to a large Latino population in the Tampa area to target with NASH trials.

QCR Clinical Research has a FibroScan and access to large Latino and Native American populations.

True Blue Clinical Research has access to a large Latino population in the Tampa area to target NASH trials.

One Network for One Solution

  • Single Contract and Centralized Budget
  • Central IRBs
  • All Sites Virtual Trial Certified
  • Virtual /Telemedicine/100% Paperless System
  • Remote and Mobile Units Available
  • Multiple Hospital Affiliations.
  • 100 Locations Across North and South America